Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Trial details
- Registry ID
- NCT06033586
- Drugs studied
- Open-label rusfertide
TrialRedline tracks 6 clinical trials sponsored by Protagonist Therapeutics, Inc.: 2 Phase 3, 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia VeraNCT06033586 | Open-label rusfertide | Active not recruiting | 2026-04-01Estimated |
| A Study of Rusfertide in Adults With Polycythemia Vera (PV)NCT05210790 | Rusfertide | Active not recruiting | 2025-02-21Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| PTG-300 in Patients With Polycythemia Vera and Elevated HematocritNCT04767802 | PTG-300 | Completed | 2023-03-15Actual |
| Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)NCT04057040 | PTG-300 | Completed | 2023-02-14Actual |
| PTG-300 in Subjects With Hereditary HemochromatosisNCT04202965 | PTG-300 | Completed | 2021-10-06Actual |
| Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative ColitisNCT02895100 | PTG-100 | Terminated | 2018-03-26Actual |
Names as written in the registry records.
NCT05210790 · Protagonist Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of subjects achieving a response who receive rusfertide compared to placebo. Description: Response is defined as absence of phlebotomy eligibility. Time frame: Week 20 through Week 32. After: Measure: Part 1a: Percentage of Participants Who Achieved Response Description: Response was defined as absence of phlebotomy eligibility. Phlebotomy eligibility was defined as either: 1) A confirmed hematocrit (HCT) greater than or equal to (≥) 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%. Time frame: From Weeks 20 to 32.